Coloplast Financials

CBHD Stock

EUR 65.08 0.28 0.43%

Financial data analysis helps to double-check if markets are presently mispricing Coloplast AS. We have analyze and collected data for thirty-six available fundamental indicators for Coloplast AS, which can be compared to its peers. The stock experiences a normal upward fluctuation. Check odds of Coloplast to be traded at €68.33 in 90 days.

Covid

Interest Hikes

Coloplast Balance Sheet Chart

At this time, Coloplast's Other Liabilities is most likely to increase significantly in the upcoming years. The Coloplast's current Retained Earnings is estimated to increase to about 18.6 B, while Total Current Liabilities is projected to decrease to roughly 7.4 B.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Key indicators impacting Coloplast's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Operating Income

6.3 B

8.4 B

Way Down

Slightly volatile

Understanding current and past Coloplast Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Coloplast's financial statements are interrelated, with each one affecting the others. For example, an increase in Coloplast's assets may result in an increase in income on the income statement.

Coloplast Stock Summary

Coloplast competes with Cerence, TELES Informationstech, BIOTIME, MBIA, and MBIA. Coloplast AS develops and markets intimate healthcare products and services worldwide. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. COLOPLAST NAM is traded on Frankfurt Stock Exchange in Germany.

Specialization	Health Care, Health Care Equipment & Services
Instrument	Germany Stock View All
Exchange	Frankfurt Exchange
ISIN	DK0060448595
Business Address	Holtedam 1-3, Humlebk,
Sector	Health Care Equipment & Supplies
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	www.coloplast.com
Phone	45 49 11 11 11
Currency	EUR - Euro

You should never invest in Coloplast without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Coloplast Stock, because this is throwing your money away. Analyzing the key information contained in Coloplast's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Coloplast Key Financial Ratios

There are many critical financial ratios that Coloplast's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Coloplast AS reports annually and quarterly.

	Revenue	27.03 B
	Gross Profit	18.93 B
	EBITDA	8.58 B
	Net Income	5.05 B
	Total Asset	48.07 B

More Fundamentals

Coloplast Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	15.8B	35.0B	48.2B	48.1B	55.3B	58.0B
Retained Earnings	8.4B	8.6B	14.6B	15.4B	17.7B	18.6B
Accounts Payable	1.0B	1.2B	1.3B	1.5B	1.7B	1.0B
Cash	448M	414M	911M	788M	709.2M	454.5M
Net Receivables	3.2B	3.9B	4.3B	4.7B	5.4B	3.7B
Good Will	2.0B	11.8B	20.0B	19.4B	22.3B	23.4B
Inventory	2.4B	3.2B	3.5B	3.7B	4.2B	2.5B
Total Liab	7.7B	26.7B	30.9B	30.1B	34.7B	36.4B
Short Long Term Debt	2.2B	1.6B	7.1B	5.1B	5.8B	6.1B
Total Current Assets	7.0B	8.8B	9.9B	10.4B	12.0B	7.9B
Intangible Assets	1.6B	8.5B	11.3B	11.0B	12.6B	13.2B
Net Debt	1.7B	17.6B	17.8B	20.9B	24.0B	25.2B
Net Invested Capital	10.3B	26.3B	36.0B	39.6B	45.5B	47.8B
Net Working Capital	680M	1.4B	(6.4B)	240M	216M	226.8M

Coloplast Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	25M	172M	638M	795M	914.3M	960.0M
Total Revenue	19.4B	22.6B	24.5B	27.0B	31.1B	20.3B
Gross Profit	13.3B	15.5B	16.3B	18.3B	21.0B	13.8B
Operating Income	6.4B	6.9B	6.8B	7.3B	8.4B	6.3B
Research Development	755M	866M	872M	913M	1.0B	736.1M
Cost Of Revenue	6.1B	7.1B	8.2B	8.8B	10.1B	6.5B
Income Before Tax	6.2B	6.1B	6.0B	6.4B	7.4B	5.4B
Net Income	4.8B	4.7B	4.8B	5.1B	5.8B	4.2B
Tax Provision	1.4B	1.4B	1.2B	1.3B	1.5B	1.4B
Net Interest Income	(45M)	(224M)	(605M)	(800M)	(720M)	(684M)
Interest Income	11M	12M	111M	80M	92M	96.6M

Coloplast Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Coloplast AS. It measures of how well Coloplast is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Coloplast brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Coloplast had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Coloplast has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (capital allocation) and investing in non-business activities like paying off debt or making acquisitions.

	2021	2022	2023	2024	2025	2026 (projected)
Change To Inventory	(403M)	(161M)	(540M)	(474M)	(290M)	(274.1M)
Change In Cash	125M	(34M)	534M	(88M)	(101.2M)	(106.3M)
Net Borrowings	848M	10.7B	622M	3.0B	3.4B	1.9B
Depreciation	745M	860M	1.1B	1.3B	1.5B	794.1M
Dividends Paid	3.8B	4.0B	4.2B	4.7B	5.4B	3.3B
Capital Expenditures	919M	927M	1.2B	1.3B	1.5B	891M
Net Income	4.8B	4.7B	4.8B	5.1B	5.8B	4.2B
End Period Cash Flow	448M	414M	911M	788M	906.2M	482.0M
Free Cash Flow	3.3B	4.0B	3.0B	1.4B	1.3B	2.6B
Other Non Cash Items	50M	52M	58M	67M	77.1M	51.8M

Coloplast Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Coloplast's current stock value. Our valuation model uses many indicators to compare Coloplast value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Coloplast competition to find correlations between indicators driving Coloplast's intrinsic value. More Info.

Coloplast AS is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Coloplast AS is roughly 2.77 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Coloplast's earnings, one of the primary drivers of an investment's value.

Coloplast AS Total Assets Over Time

Most indicators from Coloplast's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Coloplast AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coloplast AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.

The current Selling General Administrative is estimated to decrease to about 6.8 B. The current Tax Provision is estimated to decrease to about 1.4 B

	2022	2023	2025	2026 (projected)
Gross Profit	16.3B	18.3B	21.0B	13.8B
Total Revenue	24.5B	27.0B	31.1B	20.3B

Gross Profit Total Revenue

Coloplast fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Net Receivables	Good Will	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Non Current Assets Total	Non Currrent Assets Other
Total Assets		-0.73	0.83	0.97	0.96	-0.95	0.96	0.87	0.04	0.79	0.88	1.0	-0.66	0.88	-0.58	-0.79	0.99	-0.63	0.95	0.9	0.46	1.0	-0.66	0.82	1.0	0.69
Other Current Liab	-0.73		-0.69	-0.8	-0.59	0.62	-0.72	-0.62	-0.16	-0.46	-0.61	-0.74	0.36	-0.59	0.24	0.43	-0.68	0.34	-0.77	-0.67	-0.19	-0.7	0.5	-0.51	-0.73	-0.37
Total Current Liabilities	0.83	-0.69		0.8	0.79	-0.84	0.77	0.84	0.09	0.81	0.85	0.84	-0.69	0.88	-0.54	-0.7	0.83	-0.69	0.91	0.87	0.54	0.83	-0.29	0.84	0.84	0.66
Total Stockholder Equity	0.97	-0.8	0.8		0.89	-0.87	0.99	0.83	0.08	0.72	0.85	0.97	-0.61	0.83	-0.55	-0.76	0.94	-0.59	0.96	0.87	0.43	0.95	-0.7	0.75	0.97	0.68
Other Liab	0.96	-0.59	0.79	0.89		-0.96	0.88	0.84	0.06	0.82	0.84	0.95	-0.63	0.86	-0.63	-0.75	0.98	-0.62	0.86	0.86	0.39	0.97	-0.61	0.8	0.96	0.63
Net Tangible Assets	-0.95	0.62	-0.84	-0.87	-0.96		-0.86	-0.87	-0.06	-0.81	-0.87	-0.96	0.65	-0.89	0.56	0.79	-0.98	0.63	-0.87	-0.9	-0.45	-0.97	0.47	-0.83	-0.96	-0.63
Retained Earnings	0.96	-0.72	0.77	0.99	0.88	-0.86		0.83	0.06	0.74	0.85	0.96	-0.63	0.84	-0.59	-0.81	0.93	-0.61	0.95	0.86	0.47	0.95	-0.69	0.76	0.96	0.71
Accounts Payable	0.87	-0.62	0.84	0.83	0.84	-0.87	0.83		-0.07	0.93	0.98	0.87	-0.8	0.99	-0.67	-0.82	0.87	-0.82	0.84	0.97	0.64	0.87	-0.37	0.97	0.87	0.82
Cash	0.04	-0.16	0.09	0.08	0.06	-0.06	0.06	-0.07		-0.04	-0.07	0.06	0.58	-0.07	0.34	-0.04	0.02	0.45	0.0	0.13	-0.68	0.08	0.26	-0.25	0.05	-0.52
Other Assets	0.79	-0.46	0.81	0.72	0.82	-0.81	0.74	0.93	-0.04		0.86	0.78	-0.78	0.95	-0.72	-0.84	0.81	-0.86	0.76	0.9	0.56	0.79	-0.29	0.94	0.79	0.76
Net Receivables	0.88	-0.61	0.85	0.85	0.84	-0.87	0.85	0.98	-0.07	0.86		0.89	-0.79	0.97	-0.63	-0.75	0.88	-0.79	0.86	0.96	0.67	0.87	-0.42	0.93	0.88	0.83
Good Will	1.0	-0.74	0.84	0.97	0.95	-0.96	0.96	0.87	0.06	0.78	0.89		-0.65	0.88	-0.57	-0.78	0.99	-0.62	0.95	0.9	0.46	0.99	-0.64	0.81	1.0	0.68
Short Term Investments	-0.66	0.36	-0.69	-0.61	-0.63	0.65	-0.63	-0.8	0.58	-0.78	-0.79	-0.65		-0.82	0.77	0.65	-0.67	0.94	-0.72	-0.67	-0.93	-0.63	0.37	-0.91	-0.65	-0.94
Inventory	0.88	-0.59	0.88	0.83	0.86	-0.89	0.84	0.99	-0.07	0.95	0.97	0.88	-0.82		-0.68	-0.84	0.89	-0.84	0.86	0.97	0.66	0.88	-0.36	0.98	0.88	0.83
Other Current Assets	-0.58	0.24	-0.54	-0.55	-0.63	0.56	-0.59	-0.67	0.34	-0.72	-0.63	-0.57	0.77	-0.68		0.69	-0.59	0.82	-0.6	-0.53	-0.61	-0.56	0.34	-0.74	-0.58	-0.78
Other Stockholder Equity	-0.79	0.43	-0.7	-0.76	-0.75	0.79	-0.81	-0.82	-0.04	-0.84	-0.75	-0.78	0.65	-0.84	0.69		-0.79	0.73	-0.76	-0.8	-0.47	-0.8	0.34	-0.8	-0.8	-0.7
Total Liab	0.99	-0.68	0.83	0.94	0.98	-0.98	0.93	0.87	0.02	0.81	0.88	0.99	-0.67	0.89	-0.59	-0.79		-0.64	0.92	0.9	0.47	1.0	-0.63	0.83	0.99	0.69
Long Term Investments	-0.63	0.34	-0.69	-0.59	-0.62	0.63	-0.61	-0.82	0.45	-0.86	-0.79	-0.62	0.94	-0.84	0.82	0.73	-0.64		-0.67	-0.7	-0.81	-0.61	0.27	-0.9	-0.63	-0.91
Short Long Term Debt	0.95	-0.77	0.91	0.96	0.86	-0.87	0.95	0.84	0.0	0.76	0.86	0.95	-0.72	0.86	-0.6	-0.76	0.92	-0.67		0.86	0.56	0.93	-0.6	0.81	0.95	0.74
Total Current Assets	0.9	-0.67	0.87	0.87	0.86	-0.9	0.86	0.97	0.13	0.9	0.96	0.9	-0.67	0.97	-0.53	-0.8	0.9	-0.7	0.86		0.5	0.91	-0.37	0.9	0.91	0.71
Short Term Debt	0.46	-0.19	0.54	0.43	0.39	-0.45	0.47	0.64	-0.68	0.56	0.67	0.46	-0.93	0.66	-0.61	-0.47	0.47	-0.81	0.56	0.5		0.43	-0.25	0.76	0.46	0.9
Intangible Assets	1.0	-0.7	0.83	0.95	0.97	-0.97	0.95	0.87	0.08	0.79	0.87	0.99	-0.63	0.88	-0.56	-0.8	1.0	-0.61	0.93	0.91	0.43		-0.63	0.81	1.0	0.66
Common Stock	-0.66	0.5	-0.29	-0.7	-0.61	0.47	-0.69	-0.37	0.26	-0.29	-0.42	-0.64	0.37	-0.36	0.34	0.34	-0.63	0.27	-0.6	-0.37	-0.25	-0.63		-0.35	-0.65	-0.49
Property Plant Equipment	0.82	-0.51	0.84	0.75	0.8	-0.83	0.76	0.97	-0.25	0.94	0.93	0.81	-0.91	0.98	-0.74	-0.8	0.83	-0.9	0.81	0.9	0.76	0.81	-0.35		0.82	0.89
Non Current Assets Total	1.0	-0.73	0.84	0.97	0.96	-0.96	0.96	0.87	0.05	0.79	0.88	1.0	-0.65	0.88	-0.58	-0.8	0.99	-0.63	0.95	0.91	0.46	1.0	-0.65	0.82		0.69
Non Currrent Assets Other	0.69	-0.37	0.66	0.68	0.63	-0.63	0.71	0.82	-0.52	0.76	0.83	0.68	-0.94	0.83	-0.78	-0.7	0.69	-0.91	0.74	0.71	0.9	0.66	-0.49	0.89	0.69

Click cells to compare fundamentals

Coloplast Account Relationship Matchups

Coloplast fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	15.8B	35.0B	48.2B	48.1B	55.3B	58.0B
Retained Earnings	8.4B	8.6B	14.6B	15.4B	17.7B	18.6B
Accounts Payable	1.0B	1.2B	1.3B	1.5B	1.7B	1.0B
Cash	448M	414M	911M	788M	709.2M	454.5M
Net Receivables	3.2B	3.9B	4.3B	4.7B	5.4B	3.7B
Good Will	2.0B	11.8B	20.0B	19.4B	22.3B	23.4B
Inventory	2.4B	3.2B	3.5B	3.7B	4.2B	2.5B
Total Liab	7.7B	26.7B	30.9B	30.1B	34.7B	36.4B
Short Long Term Debt	2.2B	1.6B	7.1B	5.1B	5.8B	6.1B
Total Current Assets	7.0B	8.8B	9.9B	10.4B	12.0B	7.9B
Intangible Assets	1.6B	8.5B	11.3B	11.0B	12.6B	13.2B
Net Debt	1.7B	17.6B	17.8B	20.9B	24.0B	25.2B
Net Invested Capital	10.3B	26.3B	36.0B	39.6B	45.5B	47.8B
Net Working Capital	680M	1.4B	(6.4B)	240M	216M	226.8M

Coloplast February 22, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Coloplast help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Coloplast AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Coloplast AS based on widely used predictive technical indicators. In general, we focus on analyzing Coloplast Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Coloplast's daily price indicators and compare them against related drivers.

	Information Ratio	(0.05)
	Maximum Drawdown	36.1
	Value At Risk	(4.26)
	Potential Upside	3.08

Complementary Tools for Coloplast Stock analysis

When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.

	Fundamental Analysis View fundamental data based on most recent published financial statements
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	CEOs Directory Screen CEOs from public companies around the world

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC